Charlotte Gotthard M.
- Country
- Denmark
- Department
- Department of Dermatovenerology and allergy Center
Research Overview
- Efficacy and Safety of Oral Roflumilast in Adult Patients with Chronic Hand Eczema: A Randomized Controlled Trial
- Phase 3 Multicenter Evaluation of Tralokinumab with Topical Corticosteroids in Pediatric Moderate-to-Severe Atopic Dermatitis
- A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Data & Insights
Has run more than one trial at 7 of 92 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating complex dermatological conditions, with particular emphasis on chronic hand eczema (CHE) and moderate-to-severe atopic dermatitis.
- Chronic Hand Eczema Management
- Pediatric Atopic Dermatitis
- Inflammatory Skin Conditions
The investigator's work extends to both adult and pediatric populations, including infants from 6 months of age.
Therapeutic Approaches
The investigator focuses on innovative therapeutic strategies including PDE4 inhibition and targeted immunomodulation for dermatological conditions.
- Novel Therapeutic Agents
- Combination Therapy Approaches
- Topical Treatment Optimization
Their expertise includes the evaluation of combined treatment approaches using systemic and topical medications.
Clinical Outcomes
The investigator's research encompasses comprehensive assessment of skin barrier function and quality of life impacts in dermatological conditions.
- Disease Control Evaluation
- Patient Quality of Life
- Skin Microbiome Analysis
Their work includes evaluation of treatment effects on skin colonization and barrier function markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.